MartaBatusMD

Associate Professor, Internal Medicine, Rush Medical College of Rush Univ

Overview of Dr. Batus

Dr. Marta Batus is an oncologist in Chicago, IL and is affiliated with Rush University Medical Center. She received her medical degree from Rush Medical College of Rush University Medical Center and has been in practice 15 years. Dr. Batus accepts several types of health insurance, listed below. She is one of 57 doctors at Rush University Medical Center who specialize in Oncology. She also speaks multiple languages, including Polish and Russian. She has more than 40 publications and over 450 citings.

Office
1725 W Harrison St
Ste 809
Chicago, IL 60612
Book by Phone+1(872) 285-7106

Fax+1 312-942-3192

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Rush University Medical CenterResidency, Internal Medicine, 2002 - 2005
Rush Medical College of Rush University Medical CenterClass of 2002

Certifications & Licensure

IL State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Available
Join now to see all

Publications & Presentations

PubMed

Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.
Philip Bonomi, Hita Moudgalya, Sandra L Gomez, Palmi Shah, Sanjib Basu
Journal of Cachexia, Sarcopenia and Muscle. 2024-12-01
3 citations
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A ext...
Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair
Lung Cancer. 2024-10-01
2 citations
Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS).
Sarah C Tepper, Linus Lee, Michael P Fice, Conor M Jones, Evan D Klein
Surgical Oncology. 2023-08-01

Lectures

Real-world clinical burden of aggressive disease (AD) in advanced/metastatic non small cell lung cancer (aNSCLC).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

Kamneev's StoryDecember 3rd, 2020
Lung Cancer in Never SmokersNovember 8th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Polish, Russian

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment